RVNC News and Press, Revance Therapeutics Inc. From 06/30/20

- Enrollment closed with at least 76 subjects; study protocol modified in light of ongoing COVID-19 pandemic - - Revance now expects to report topline results from JUNIPER trial in early 2021 - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovativ...

Revance Therapeutics (NASDAQ: RVNC ) announces positive results from two open-label dose-escalating Phase 2a clinical trials evaluating DaxibotulinumtoxinA (DAXI) for the treatment of dynamic forehead lines following glabellar (frown) line injections and lateral canthal lines (crow...

- At least one dose in each study demonstrated a measurable treatment effect in 100% of subjects at 4 weeks, with median duration of 27 weeks in forehead lines and 24 weeks in crow’s feet - - DaxibotulinumtoxinA for Injection was well tolerated across all doses in both indicatio...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will participate in the 40th Annual William B...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will present at the Goldman Sachs 41 st Annu...

- First neurotoxin formulation to be developed as a potential biosimilar product to BOTOX ® , potentially giving Mylan access to 14 indications upon approval - - $30 million milestone payable to Revance from Mylan - Revance Therapeutics, Inc. (NASDAQ: RVNC) and Mylan N.V. (NASDAQ...

Allergan ( ABBV -1.0% ) competitor Evolus ( EOLS +30.5% ), maker of Botox (onabotulinumtoxinA) rival Jeuveau (prabotulinumtoxinA-xvfs), jumps on a 10x surge in volume burning short sellers along the way. More news on: AbbVie Inc., Evolus, Inc., Revance Therapeutics, Inc....

Revance Therapeutics (NASDAQ: RVNC ) has agreed to acquire privately held Hint, Inc., doing business as HintMD , the developer of an integrated financial platform for the aesthetics industry, for 8.54M shares of RVNC common stock (~$180M based on yesterday's close of $21.08). More news ...

- Provides access to a $500+ million market opportunity in U.S aesthetic practice payment services - - Leverages planned commercial infrastructure across both premium facial injectables products and services platform - - Unique, differentiated and integrated digital services pla...

Privately held Galderma announces the results from a 120-subject study, DREAM, assessing the safety and patient satisfaction of Dysport (abobotulinumtoxinA) for the temporary treatment of moderate-to-severe glabellar lines (frown lines) between the eyebrows in adults less than 65 years old...